PRISMS: remote high resolution in situ multispectral imaging of wall paintings

The non-invasive monitoring and examination of wall paintings in grotto sites, tombs and buildings is particularly important since these paintings are often extremely vulnerable. Traditionally, inspection of wall paintings at high resolution (i.e. sub-millimetre resolution) requires either scaffolding or some heavy and cumbersome mechanical structure to lift a person or camera to the upper parts of a wall or ceiling. We have developed a proto-type portable remote imaging multi-spectral camera that operates at ground level for in situ high-resolution colour and spectral imaging of wall paintings. We present here the latest developments for the instrument and examples of how the instrument can be used for diagnosis of wall paintings

PRISMS: a portable multispectral imaging system for remote in situ examination of wall paintings

We present a proto-type portable remote multispectral imaging system, PRISMS (Portable Remote Imaging System for Multispectral Scanning), that is light-weight, flexible and without any cumbersome mechanical structure for in situ high resolution colour and spectral imaging of large and inaccessible paintings such as wall paintings. This is the first instrument to be able to image paintings at inaccessible heights in situ from ground level to produce not only high resolution colour images but also multispectral images

Pigment identification with optical coherence tomography and multispectral imaging

We describe a new method for non-invasive pigment identification by combining the spectral reflectance in the visible spectrum with near infrared OCT cross-section images of the subsurface layer structure

Policing vulnerability in sex work: the harm reduction compass model

This paper explores the current approach to the interaction between policing and sex work in England and Wales. It reviews the legal and policy context and outlines current policing guidance and priorities, introducing the Harm Reduction Compass as a mechanism to advance policing policy and optimise operational decision-making. Through critical discussion of occupational culture and reforms in policing, it also assesses how continuity, reliability, and transferability can be achieved across police forces within the existing hostile and outdated statutory framework. The Harm Reduction Compass (HRC) aims to focus policing resources on adult sexual exploitation and crimes experienced by sex workers by decoding the complexities of different individuals’ personal circumstances. This paper proposes a new framework as a model to aid operational policing by triaging different scenarios to reach the most appropriate response. This new model, which identifies autonomy and harm as the most significant indicators, addresses harm and vulnerability holistically and combines policing with public health and community-based approaches; this ensures the pathway to assistance and intervention is an integrated multi-partnership. The HRC is a step forward in progressing police culture around the use of language and in dealing with crimes against sex workers in the most appropriate way

Retinal vasculitis and intraocular inflammation after intravitreal injection of Brolucizumab

Purpose: To evaluate features and outcomes of eyes with retinal vasculitis and intraocular inflammation (IOI) after intravitreal injection (IVI) of brolucizumab 6 mg/0.05 ml for treatment of neovascular age-related macular degeneration. Design: Retrospective case series. Participants: Fifteen eyes from 12 patients identified from 10 United States centers. Methods: Review of patient demographics, ophthalmologic examination results, and retinal imaging findings. Main Outcome Measures: Baseline and follow-up visual acuity (VA), prior anti–vascular endothelial growth factor (VEGF) injections, clinical presentation, retinal findings, fluorescein angiography results, and treatment strategies. Results: The number of previous anti-VEGF IVIs ranged between 2 and 80 in the affected eye before switching to brolucizumab. Retinal vasculitis and IOI were diagnosed at a mean of 30 days after brolucizumab IVI. Mean VA before brolucizumab IVI was 0.426 logarithm of the minimum angle of resolution (logMAR; Snellen equivalent, 20/53) and VA at diagnosis of retinal vasculitis was 0.981 logMAR (Snellen equivalent, 20/191; range, 20/25–20/1600; P = 0.008). All affected eyes showed IOI with variable combinations of focal or elongated segmental sheathing and discontinuity of small and large retinal arteries, sclerotic arteries, regions of vascular nonperfusion, cotton-wool spots, Kyrieleis plaques, irregular venous caliber with dilated and sclerotic segments, perivenular hemorrhages, and foci of phlebitis. Fluorescein angiography revealed delayed retinal arterial filling, retinal vascular nonperfusion, and variable dye leakage from affected vessels and the optic nerve. Systemic evaluation for embolic causes was unrevealing in 2 patients, and 3 patients showed negative laboratory assessment for uveitis. Treatment consisted of various combinations of corticosteroids (systemic, intravitreal, and topical), and 2 eyes underwent vitrectomy without improvement in vision. After a mean follow-up of 25 days, mean VA was 0.833 logMAR (Snellen equivalent, 20/136), which was reduced compared with baseline (P = 0.033). Conclusions: Retinal vasculitis and IOI after brolucizumab IVI are characterized by variable occlusion of large or small retinal arteries, or both, and perivenular abnormalities. It may span from peripheral vasculitis to occlusion of large retinal arteries around the optic nerve or macula with severe vision loss. A high index of suspicion is required because vitreous cells may obscure visualization of retinal details. © 2020 American Academy of Ophthalmolog